ÖZGÜROĞLU, M. Et Al. 2021. Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .

ÖZGÜROĞLU, M., Alva, A. S., Csoszi, T., Matsubara, N., Geczi, L., Cheng, S. Y., ... Fradet, Y.(2021). Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

ÖZGÜROĞLU, Mustafa Et Al. "Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

ÖZGÜROĞLU, Mustafa Et Al. "Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021

ÖZGÜROĞLU, M. Et Al. (2021) . "Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.

@article{article, author={Mustafa ÖZGÜROĞLU Et Al. }, title={Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}